Terfenadine
Terfenadine is a histamine H1-receptor antagonist, which blocks HERG and KATP (KIR6) channels. (In Vitro) :Terfenadine ((±) -Terfenadine) (4-20 μM; 24 hours) induces dose and time-dependent apoptosis on A375 melanoma cells. The IC50 after 24 h of TEF treatment in complete medium was 10.4 μM for A375 cells, 9.9 μM for Hs294T cells and 9.6 for HT144 cells.Terfenadine (2-10 μM; 8 hours) induces dose-dependent cytotoxicity.Terfenadine (10 μM; 8 hours) causes a massive vacuolization of the cytoplasm and autophagic vacuoles of both double and multiple membranes and at various stages. Terfenadine induces autophagy by ROS-dependent and -independent mechanisms. (In Vivo) :Terfenadine (p.o.; 40 mg/kg; for 16 days) produces a significant inhibition of tumour growth rate and enhances the anti-cancer effect of EPI in chemo-resistant NSCLC xenograft models.
Product Specifications
CAS Number
50679-08-8
Product Name Alternative
MDL 9918 | NSC 665802 | (±) -Terfenadine | DL-Terfenadine
Field of Research
Pharmacology & Drug Discovery
Purity
>98% (HPLC)
Solubility
Water: 0.0963 mg/L
Smiles
OC (C1=CC=C (C (C) (C) C) C=C1) CCCN2CCC (C (C3=CC=CC=C3) (O) C4=CC=CC=C4) CC2
Molecular Formula
C32H41NO2
Molecular Weight
471.67
Storage Conditions
Storage temperature: -20°C. Stability: ≥ 2 years
Notes
For research use only.
Other Product Names
1- (4- (tert-butyl) phenyl) -4- (4- (hydroxydiphenylmethyl) piperidin-1-yl) butan-1-ol
Available Sizes
Frequently Asked Questions
Explore Other Products
Browse additional items from our catalog
Lentiviral human SPRYD3 shRNA (UAS) - Lentiviral human SPRYD3 shRNA (UAS, RFP) (25)
Anti-Condensin complex subunit 1 Antibody (2N470)